Realty Income Corp
Change company Symbol lookup
Select an option...
O Realty Income Corp
CM Canadian Imperial Bank of Commerce
SFRFF Silver Fields Resources Inc
BAC Bank of America Corp
CHKJQ Chesapeake Energy Corp
ESPR Esperion Therapeutics Inc
AMZN Amazon.com Inc
VEEV Veeva Systems Inc
AVGO Broadcom Inc
IAU iShares Gold Trust
Go

Real Estate : Equity Real Estate Investment Trusts (REITs) | Mid Cap Blend
Company profile

Realty Income Corporation is a real estate investment trust (REIT). The Company is engaged in in-house acquisition, portfolio management, asset management, credit research, real estate research, legal, finance and accounting, information technology and capital markets capabilities. As of December 31, 2016, the Company owned a diversified portfolio of 4,944 properties located in 49 states and Puerto Rico, with over 83.0 million square feet of leasable space leased to 248 different commercial tenants doing business in 47 separate industries. As of December 31, 2016, of the 4,944 properties in the portfolio, 4,920, or 99.5%, were single-tenant properties, and the remaining were multi-tenant properties. As of December 31, 2016, of the 4,920 single-tenant properties, 4,836 were leased with a weighted average remaining lease term (excluding rights to extend a lease at the option of the tenant) of approximately 9.8 years.

Closing Price
$61.67
Day's Change
1.74 (2.90%)
Bid
--
Ask
--
B/A Size
--
Day's High
62.02
Day's Low
60.86
Volume
(Below Average)
Volume:
2,256,399

10-day average volume:
2,560,141
2,256,399

QurAlis Announces Agreement to Strengthen ALS Pipeline

7:00 am ET July 1, 2020 (BusinessWire) Print

QurAlis Corporation, a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced an agreement to in-license pre-clinical compounds with disease modifying potential in ALS by preventing disease-induced neuronal excitotoxicity from Eli Lilly and Company (Lilly). Financial terms were not disclosed.

"We believe that the compounds we are in-licensing from Lilly have great potential for the development of a targeted ALS therapy, and we intend to advance these compounds to the clinic and to patients in need," said Kasper Roet, Ph.D., CEO of QurAlis. "Our ultimate goal has always been to develop clinically meaningful disease modifying medicines for ALS, and this agreement represents a big step in that direction."

Excitotoxicity in ALS, a defining characteristic of the disease, is caused by the hyperactivity of neurons that leads to the internal buildup of toxic proteins and metabolic waste, and the subsequent death of brain and spinal cord motor neurons. By aiming to prevent neuronal excitability with specifically targeted small molecule drugs, QurAlis' excitotoxicity research program intends to halt this process and prevent disease progression in those ALS patients, where this disease process plays a prominent role.

"Data from ALS patient-derived stem cell models suggest that excitotoxicity is a major driver of motor neuron degeneration in ALS. The compounds included in this licensing agreement will enable us to target neuronal excitotoxicity in ALS in a novel way," commented Dan Elbaum, Ph.D., CSO of QurAlis. "We are very encouraged by the signs of activity from early clinical trials on this pathway, which suggest that we may be able to prevent the toxicity to neurons typical of ALS and hopefully modify the course of the disease."

About ALS

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disease impacting nerve cells in the brain and spinal cord. ALS breaks down nerve cells, reducing muscle function and causing loss of muscle control. ALS can be traced to mutations in over 25 different genes and is often caused by a combination of multiple sub-forms of the condition. Its average life expectancy is three years, and there is currently no cure for the disease.

About QurAlis Corporation

QurAlis is bringing hope to the ALS community by developing breakthrough precision medicines for this devastating disease. Our stem cell technologies generate proprietary human neuronal models that enable us to more effectively discover and develop innovative therapies for genetically validated targets. We are advancing three antisense and small molecule programs addressing sub-forms of the disease that account for the majority of patients. Together with a world-class network of thought leaders, drug developers and patient advocates, our team is rising to the challenge of conquering ALS. www.quralis.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200701005171/en/

SOURCE: QurAlis Corporation

MacDougall
Shai Biran, Ph.D.
(781) 235-3060
sbiran@macbiocom.com
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.